Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow MRK
Merck & Co., Inc. (MRK) EPS (diluted)
Merck & Co., Inc.'s EPS (diluted) for fiscal 2025 was $7.28, up 8.01% from $6.74 in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.25. Over the past ten years it has ranged from $0.14 (fiscal 2023) to $7.28 (fiscal 2025) — the current reading is the highest in ten years. Merck & Co., Inc. ranks 12th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $7.28 | 8.01% |
| FY2024 | $6.74 | 4,714.29% |
| FY2023 | $0.14 | (97.55%) |
| FY2022 | $5.71 | 11.09% |
| FY2021 | $5.14 | 84.89% |
| FY2020 | $2.78 | (27.03%) |
| FY2019 | $3.81 | 64.22% |
| FY2018 | $2.32 | 149.46% |
| FY2017 | $0.93 | (34.23%) |
| FY2016 | $1.41 | (9.35%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.54 | — |
| Mar 2026 | −$1.72 | — |
| Dec 2025 | $1.19 | (48.71%) |
| Sep 2025 | $2.32 | 31.82% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $16.09 |
| JNJ Johnson & Johnson compare | $8.63 |
| AZN AstraZeneca PLC compare | $6.69 |
| NVS Novartis AG compare | $6.63 |
| NVO Novo Nordisk A/S compare | $4.09 |
| ABBV AbbVie Inc. compare | $3.54 |
| MRK Merck & Co., Inc. | $1.25 |
| PFE Pfizer Inc. compare | $0.76 |
| GILD Gilead Sciences, Inc. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement